Evidence map›Paper›PMID 21900958›Full record

ArticleCell death & disease2011

Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models.

M Seervi, J Joseph, P K Sobhan, B C Bhavya, T R Santhoshkumar

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Heat shock proteins-driven stress granule dynamics: yet another avenue for cell survival.Apoptosis : an international journal on programmed cell death · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
  20. Juglone exerts antitumor effect in ovarian cancer cells.Iranian journal of basic medical sciences · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M SeerviIntegrated Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
J Joseph
P K Sobhan
B C Bhavya
T R Santhoshkumar
Rajiv Gandhi Centre for Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial cytochrome c (cyt. c) release and caspase activation are often impaired in tumors with Bcl-2 overexpression or Bax and Bak-defective status. Direct triggering of cell death downstream of Bax and Bak is an attractive strategy to kill such cancers. Small molecule compounds capable of direct caspase activation appear to be the best mode for killing such tumors. However, there is no precise model to screen such compounds. The currently employed cell-free systems possess the inherent drawback of lacking cellular contents and organelles that operate in integrating cell death signaling. We have developed highly refined cell-based approaches to validate direct caspase activation in cancer cells. Using this approach, we show that PAC-1 (first procaspase-activating compound), the first direct activator of procaspases identified in a cell-free system, in fact requires mitochondrial cyt. c release for triggering caspase activation similar to other antitumor agents. It can induce significant caspase activation and cell death in the absence of Bax and Bak, and in cells overexpressing Bcl-2 and Bcl-xL. This study for the first time defines precise criteria for the validation of direct caspase-activating compounds using specialized cellular models that is expected to accelerate the discovery of potential direct caspase activators.

Indexed as

bcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinCaspasesCell Line, TumorCytochromes cEnzyme ActivationGene Knockout TechniquesHumansHydrazonesMitochondriaPiperazinesProtein PrecursorsProto-Oncogene Proteins c-bcl-2(4-benzylpiperazin-1-yl)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazinebcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinCaspasesCytochromes cHydrazonesPiperazinesProtein PrecursorsProto-Oncogene Proteins c-bcl-2

Identifiers

PMID21900958
PMCPMC3186908
OpenAlexW2050317062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.